Toxic multinodular goiter medical therapy

Toxic multinodular goiter Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic multinodular goiter from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Toxic multinodular goiter medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic multinodular goiter medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic multinodular goiter medical therapy
CDC on Toxic multinodular goiter medical therapy
Toxic multinodular goiter medical therapy in the news
Blogs on Toxic multinodular goiter medical therapy
Directions to Hospitals Treating Toxic multinodular goiter
Risk calculators and risk factors for Toxic multinodular goiter medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

• The mainstay of treatment for Toxic multinodular goiter is Surgery.
• Patients with symptomatic hyperthyroidism, sub-clinical hyperthyroid patients with expected compilations and patients refusing surgical therapy are treated with beta blockers and anti-thyroid pharmacological groups.

Medical Therapy

Indications

Pharmacologic medical therapy for toxic multinodular goiter (TMG) is recommended for the patients with the following:

• Symptomatic hyperthyroidism
• Sub-clinical hyperthyroid
• Patients refusing surgical therapy.

Treatment of TMG is based on:

• Severity of disease
• Biochemical evaluation of thyroid profile level of TSH, T3, and T4
• Cardiac evaluation(echocardiogram, electrocardiogram, Holter monitor, or myocardial perfusion studies)
• Neuromuscular complications
• Age
• Size of goiter

Pharmacological drug therapy

Pharmacologic medical therapy for toxic multinodular goiter mainly depends on beta blockers and anti-thyroid class.

• Thyroid storm
  • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
  • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
  • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
  • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
  • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
  • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
• Hyperthyroidism
  • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
  • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
  • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
  • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
  • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
  • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
• Subclinical hyperthyroidism with comorbid conditions
  • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
  • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
  • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
  • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
  • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
  • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
• Subclinical hyperthyroidism without comorbid conditions
  • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
  • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
  • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
  • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
  • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
  • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days